Uniphos Enterprises per share figures

Share price at each year-end
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
₹2.91₹2.98₹0.04₹5.55₹5.64
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
₹3.06₹2.98₹0.04₹5.55₹5.64
₹351.82₹351.82₹394.22₹298.43₹431.02
₹3.76₹4.60₹16.03₹7.28₹0.21
—−₹0.49−₹0.39−₹0.50−₹0.21
−₹0.49−₹0.49−₹0.39−₹0.50−₹0.21
—₹0.50₹5.70₹6.50₹5.65
7.07.07.07.07.0
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

UNIENTER₹85.24

Uniphos Enterprises Limited

· Chemicals
₹ CrorePeersVINYLINDIASRDMcap ₹593 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
₹ per share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Basic EPS5.645.550.042.982.91
Diluted EPS5.645.550.042.983.06
Book Value per Share431.02298.43394.22351.82351.82
Revenue per Share0.217.2816.034.603.76
Cash Flow per Share-0.21-0.50-0.39-0.49—
Free Cash Flow per Share-0.21-0.50-0.39-0.49-0.49
Dividends per Share5.656.505.700.50—
Shares Outstanding (cr)7.07.07.07.07.0
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.